KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Cash & Equivalents: 2017-2025

Historic Cash & Equivalents for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to $129.1 million.

  • Aquestive Therapeutics' Cash & Equivalents rose 65.69% to $129.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.1 million, marking a year-over-year increase of 65.69%. This contributed to the annual value of $71.5 million for FY2024, which is 199.71% up from last year.
  • Aquestive Therapeutics' Cash & Equivalents amounted to $129.1 million in Q3 2025, which was up 113.20% from $60.5 million recorded in Q2 2025.
  • Aquestive Therapeutics' Cash & Equivalents' 5-year high stood at $129.1 million during Q3 2025, with a 5-year trough of $14.7 million in Q1 2022.
  • Its 3-year average for Cash & Equivalents is $62.8 million, with a median of $68.7 million in 2025.
  • Per our database at Business Quant, Aquestive Therapeutics' Cash & Equivalents slumped by 48.31% in 2022 and then skyrocketed by 300.56% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Cash & Equivalents (Quarterly) stood at $28.0 million in 2021, then fell by 2.68% to $27.3 million in 2022, then dropped by 12.47% to $23.9 million in 2023, then skyrocketed by 199.71% to $71.5 million in 2024, then surged by 65.69% to $129.1 million in 2025.
  • Its Cash & Equivalents was $129.1 million in Q3 2025, compared to $60.5 million in Q2 2025 and $68.7 million in Q1 2025.